Platinum resistant
Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase Ill OVATURE multicenter randomized study
... Purpose: Platinum resistant ovarian cancer (PROC) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic ...of platinum would increase activity, the aim of the present ...
41
A Pilot Study of Gemcitabine and Epirubicin Combination Chemotherapy as a Salvage Regimen for Recurrent Platinum Resistant and/or Refractory Epithelial Ovarian Cancer
... with platinum-resistant ovarian ...with platinum-resistant ovarian cancer, the overall tumor response rate was ...recurrent platinum resistant and/or refractory disease (PFI < ...
7
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
... with platinum-resistant ovarian carcinoma, the mechanisms underlying these phenomena have not yet been character- ...in platinum-resistant ovarian cancer cells ...in ...
11
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
... rent, platinum-resistant setting, bevacizumab monotherapy is well tolerated and appears to have a comparable activity to other nonplatinum chemotherapeutic agents currently in ...for ...
17
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
... of platinum-resistant recurrent ovarian cancer ...with platinum-resistant recurrent ovarian cancer treated with apatinib combined with toptecan therapy were analyzed and followed up for 3 ...
7
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
... diagnosis. Platinum-resistant OC can be treated with cytotoxic chemotherapy such as paclitaxel, topotecan, pegylated liposomal doxorubicin, and gemcitabine, but many patients eventually relapse upon ...
13
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
... cancer, platinum resistant disease and treatment”, was performed from 2000 to 2010 in order to identify novel targets for recurrent, platinum-resistant ovarian cancer; only articles written in ...
14
Ribonucleotide reductase inhibition restores platinum sensitivity in platinum resistant ovarian cancer: a Gynecologic Oncology Group Study
... restored platinum-sensitivity in platinum-resistant ovarian ...in platinum-resistant ovarian cancer cells are clinically ...with platinum-resistant ovarian cancer treated ...
10
Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer
... duce platinum resistance in EOC ...to platinum resistance or not in EOC was unclear ...the platinum resistance in EOC ...the platinum-resistant patients compared to the sensitive ...
10
Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer
... A literature search was performed in Pubmed/medline, Google, ClinicalTrials.gov and web site of pharmaceutical companies using the terms “vintafolide – EC145 and ovarian cancer,” “folate receptor,” and ...
8
Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide
... chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of first-line chemotherapy for patients with advanced ovarian ...cancer. Platinum-resistant ovarian cancer can be ...
12
<p>Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study</p>
... from platinum-resistant epithelial ovarian cancer patients who received apatinib treatment between January 2015 and November 2018 at the First Af fi liated Hospital of Wenzhou Medical ...
6
Altered glutamine metabolism in platinum resistant ovarian cancer
... with platinum resistance in various cancer types [42-45] for example via repression of c-MYC inhibitor bridging integrator 1 [44] or increased platinum accumulation in cells ...induced platinum ...
13
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
... further platinum-based chemotherapy treatments. The prog- nosis of this patient subgroup is generally poor with overall survival (OS) of less than 12 months (1). The treatment of these patients should therefore be ...
6
Pegylated liposomal doxorubicin in the management of ovarian cancer
... of platinum-refractory and primary platinum- resistant patients, a statistically significant advantage in favor of the combination was observed in terms of response rate ...of ...
21
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
... of platinum resistance and stem-like properties in primary HGSOC patient-derived platinum-resistant ...of platinum resistance by maintaining stem-like properties in ...overcomes ...
15
New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools
... different resistant tu- mors, which probably reflects the selection of one of the different subpopulations, but each of these markers are re- lated to the physiology of CSCs ...from ...
14
Similar chromosomal changes in cisplatin resistant and oxaliplatin resistant sublines of the H69 SCLC cell line are not associated with platinum resistance
... by platinum drug treatment contributes to platinum resistance; we have analysed H69 SCLC cells and two low-level platinum-resistant sublines, H69CIS200 and H69OX400, derived by cisplatin and ...
29
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway
... a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor ...with platinum in ...of platinum resistant ovarian ...
14
Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management
... recurrent platinum-sensitive and in the platinum-resistant ...in platinum-sensitive, recurrent pelvic serous cancers has shown an improvement in RR and PFS but a slightly higher incidence of ...
9